114 related articles for article (PubMed ID: 3881681)
1. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest.
Einat M; Resnitzky D; Kimchi A
Nature; 1985 Feb 14-20; 313(6003):597-600. PubMed ID: 3881681
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.
Bragazzi Cunha J; Leix K; Sherman EJ; Mirabelli C; Frum T; Zhang CJ; Kennedy AA; Lauring AS; Tai AW; Sexton JZ; Spence JR; Wobus CE; Emmer BT
J Virol; 2023 Dec; 97(12):e0127623. PubMed ID: 37975674
[TBL] [Abstract][Full Text] [Related]
3. Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined
Heishima K; Sugito N; Abe C; Hirata A; Sakai H; Akao Y
Mol Ther Nucleic Acids; 2023 Sep; 33():960-982. PubMed ID: 37727442
[TBL] [Abstract][Full Text] [Related]
4. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.
Qin A
Front Oncol; 2023; 13():1173467. PubMed ID: 37182173
[TBL] [Abstract][Full Text] [Related]
5. SRSF1 acts as an IFN-I-regulated cellular dependency factor decisively affecting HIV-1 post-integration steps.
Sertznig H; Roesmann F; Wilhelm A; Heininger D; Bleekmann B; Elsner C; Santiago M; Schuhenn J; Karakoese Z; Benatzy Y; Snodgrass R; Esser S; Sutter K; Dittmer U; Widera M
Front Immunol; 2022; 13():935800. PubMed ID: 36458014
[TBL] [Abstract][Full Text] [Related]
6. Decoding the pathogenesis of Diamond-Blackfan anemia using single-cell RNA-seq.
Wang B; Wang C; Wan Y; Gao J; Ma Y; Zhang Y; Tong J; Zhang Y; Liu J; Chang L; Xu C; Shen B; Chen Y; Jiang E; Kurita R; Nakamura Y; Lim KC; Engel JD; Zhou J; Cheng T; Zhu X; Zhu P; Shi L
Cell Discov; 2022 May; 8(1):41. PubMed ID: 35534476
[TBL] [Abstract][Full Text] [Related]
7. MYC Controls the Epstein-Barr Virus Lytic Switch.
Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
[TBL] [Abstract][Full Text] [Related]
9. STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells.
Liu Y; Lv J; Liu J; Liang X; Jin X; Xie J; Zhang L; Chen D; Fiskesund R; Tang K; Ma J; Zhang H; Dong W; Mo S; Zhang T; Cheng F; Zhou Y; Jia Q; Zhu B; Kong Y; Guo J; Zhang H; Hu ZW; Cao X; Qin FX; Huang B
J Clin Invest; 2018 Mar; 128(3):1057-1073. PubMed ID: 29431732
[TBL] [Abstract][Full Text] [Related]
10. Covalent ISG15 conjugation to CHIP promotes its ubiquitin E3 ligase activity and inhibits lung cancer cell growth in response to type I interferon.
Yoo L; Yoon AR; Yun CO; Chung KC
Cell Death Dis; 2018 Jan; 9(2):97. PubMed ID: 29367604
[TBL] [Abstract][Full Text] [Related]
11. Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
Musella M; Manic G; De Maria R; Vitale I; Sistigu A
Oncoimmunology; 2017; 6(5):e1314424. PubMed ID: 28638743
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus: more than 50 years old and still providing surprises.
Young LS; Yap LF; Murray PG
Nat Rev Cancer; 2016 Dec; 16(12):789-802. PubMed ID: 27687982
[TBL] [Abstract][Full Text] [Related]
13. Interferon-α inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling.
Nguyen TP; Bazdar DA; Mudd JC; Lederman MM; Harding CV; Hardy GA; Sieg SF
J Leukoc Biol; 2015 Jun; 97(6):1139-46. PubMed ID: 25784743
[TBL] [Abstract][Full Text] [Related]
14. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA; Morrison SL; Timmerman JM
Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma.
Ye H; Tong J; Wu J; Xu X; Wu S; Tan B; Shi M; Wang J; Zhao W; Jiang H; Jin S
Int J Nanomedicine; 2014; 9():4533-50. PubMed ID: 25288882
[TBL] [Abstract][Full Text] [Related]
16. Type I interferons induce autophagy in certain human cancer cell lines.
Schmeisser H; Fey SB; Horowitz J; Fischer ER; Balinsky CA; Miyake K; Bekisz J; Snow AL; Zoon KC
Autophagy; 2013 May; 9(5):683-96. PubMed ID: 23419269
[TBL] [Abstract][Full Text] [Related]
17. Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands.
Apelbaum A; Yarden G; Warszawski S; Harari D; Schreiber G
Mol Cell Biol; 2013 Feb; 33(4):800-14. PubMed ID: 23230268
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress.
Xiao N; Jani K; Morgan K; Okabe R; Cullen DE; Jesneck JL; Raffel GD
Blood; 2012 May; 119(21):4898-907. PubMed ID: 22490678
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative Properties of Type I and Type II Interferon.
Bekisz J; Baron S; Balinsky C; Morrow A; Zoon KC
Pharmaceuticals (Basel); 2010 Mar; 3(4):994-1015. PubMed ID: 20664817
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
